Document is current
Any future updates will be listed below
-
Authors
Eberhard, Anna http://orcid.org/0000-0001-9408-4150
Bergman, Stefan
Mandl, Thomas
Olofsson, Tor
Rydholm, Maria
Jacobsson, Lennart
Turesson, Carl
-
Funding
Funding for this research was provided by:
The Swedish Research Council (2015-02228)
The Swedish Rheumatism Association (R-664091)
Lund University (ALFSKANE-446501)
- License Information
-
More Information
Article History
Received: 16 February 2021
Accepted: 25 May 2021
First Online: 14 June 2021
Declarations
:
: The study was approved by the Regional Ethical Review Board for southern Sweden (Lund, Sweden: LU 410-94), and was conducted in accordance with the declaration of Helsinki. All participants gave their written informed consent to participate in the study.
: Not applicable.
: C.T. has received consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. T.M. is an employee of the pharmaceutical company Novartis, working as medical advisor in rheumatology. Jacobsson L.T.H. has received lecture and consulting fees from Pfizer, Abbvie, Novartis, Eli-Lily, and Janssen. T.O. has performed consulting tasks for Eli Lilly, and Merck Sharp & Dohme unrelated to the present work.
